Merck & Co., Inc. Restricted Cash
Merck & Co., Inc. (MRK) had Restricted Cash of $68.00 million as of 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2024-02-26
- 2023-12-31: Restricted Cash $68.00M.
- 2022-12-31: Restricted Cash $79.00M.
- 2021-12-31: Restricted Cash $71.00M.
- 2020-12-31: Restricted Cash $103.00M.
| Period end | Restricted Cash |
|---|---|
| 2023-12-31 | $68.00M 10-K · filed 2024-02-26 |
| 2022-12-31 | $79.00M 10-K · filed 2024-02-26 |
| 2021-12-31 | $71.00M 10-K · filed 2024-02-26 |
| 2020-12-31 | $103.00M 10-K · filed 2024-02-26 |
| 2019-12-31 | $258.00M 10-K · filed 2023-02-24 |
| 2018-12-31 | $2.00M 10-K · filed 2020-02-26 |
| 2017-12-31 | $4.00M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |